1 / 26

ACRIN Gynecologic Committee

ACRIN Gynecologic Committee. Fall Meeting 2010. ACRIN 6695.

bo-sears
Download Presentation

ACRIN Gynecologic Committee

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ACRIN Gynecologic Committee Fall Meeting 2010

  2. ACRIN 6695 Perfusion CT (DCE-CT) as an early predictor of response to combined cytotoxic and anti-angiogenic chemotherapy and as a surrogate marker of long-term outcome for patients with advanced stage epithelial ovarian, peritoneal and fallopian tube cancer: A companion study to GOG 262 Chaan Ng

  3. Overall survival • Response • Biomarkers in oncology • -Assessment of tumor response • -Predictors of response • -Prognostic markers • CEA, PSA, Ca125 • TNM • RECIST BACKGROUND: Biomarkers

  4. BACKGROUND: CT Perfusion • CT Perfusion • Tissue viability • Angiogenesis • Functional evaluation • Tumor blood flow, volume, permeability • Combined with routine CT staging

  5. BACKGROUND: “THE QUESTION” • Utility of CT perfusion in oncology • Translatability of CT perfusion into clinical environment

  6. BACKGROUND: THE STUDY • ACRIN 6695 • GOG 262

  7. PROTOCOL SCHEMA

  8. “Conventional” “Dose-dense” •Primary Endpoint: -Progression-free survival (PFS) •Secondary Endpoints: -Overall Survival (OS) -Response Rate (RR) -Toxicity -Translational Research -Quality of Life

  9. IMAGING OBJECTIVES: Primary • Whether larger changes in tumor perfusion parameters (T2 - T0) are predictive of better progression-free-survival rate at 6 months (PFS6m) • [Early predictorof response?] • [Prior to first routine CT restaging]

  10. Contrast body CT

  11. TARGET LESION • Precontrast • >1cm short axis • > 10 HU on pre-contrast (50% of lesion) • Postcontrast • > 5 HU enhancement (in 50% of lesion)

  12. CT CONTRAST • Oral contrast • Negative or positive contrast • IV contrast • >300 mgI2/mL • 3-4 mL/s • 0.8 mL/kg body weight (max. 70 mL volume)

  13. TARGET LESION: examples

  14. TARGET LESION: examples

  15. TARGET LESION • > 2cm • Round or oval • Not plaques • Avoid motion • Retroperitoneum • Pelvis • Enhancement • Cyst, ascites, hematoma • Postop changes

  16. ELIGIBILITY • Eligible for GOG • Adequate renal function • No contraindication to IV contrast medium • Diabetics on Metformin • Consent process • Correlative within Consent Form of participating GOG sites, with “opt-out”

  17. ANALYSES • Central perfusion CT data analysis • Ting Lee • ACRIN HQ • Data available for alternative analyses • GE model • Other vendors

  18. ACCRUAL • ACRIN = 70 evaluable • GOG = 625 • Attrition • In practice we need 25-30% of GOG accrual

  19. CHALLENGES • Accrual • Sites • GOG • Target lesions • Radiationdose

  20. SITES • Looking for collaborating sites

  21. CONTACT DETAILS • Chaan Ng • Department of Radiology • MD Anderson Cancer Center • Houston, TX 77030-4009 • Phone: 713-792-6759 • Email:cng@mdanderson.org • Ting-Yim Lee • Imaging Research Labs, • Robarts Research Institute • London, Ontario, Canada • Phone: 519-663-5777 ext. 24131 • Email: tlee@imaging.robarts.ca

More Related